

Ardizzoni et al, Journal for ImmunoTherapy of Cancer, TAIL final analysis

Supplemental Table 1. SAEs and irAEs in all patients and selective subgroups

	Atezolizumab (N=615)	Sqm (n=153)	Nsqm (n=461)	ECOG PS 0/1 (n=554)	ECOG PS 2 (n=61)	Age ≥75 years (n=76)	Prior anti-PD-1 (n = 40)	OAK- like (n=424)	Renal impairment (n=79)	AID (n=30)	Active/ chronic hepatitis (n=14)	CNS metastases (n=90)	Liver metastases (n=136)	EGFR + (n=40)
No. of deaths	473 (77)	125 (82)	348 (76)	417 (75)	56 (92)	60 (789)	36 (90)	306 (72)	65 (82)	28 (93)	11 (79)	76 (84)	123 (90)	30 (75)
No. of patients with ≥1:														
AE	564 (92)	141 (92)	422 (92)	512 (92)	52 (85)	71 (93)	37 (93)	389 (92)	77 (98)	28 (93)	13 (93)	81 (90)	119 (88)	32 (80)
Related AE	340 (55)	85 (56)	254 (55)	310 (56)	30 (49)	44 (58)	13 (33)	240 (57)	57 (72)	22 (73)	11 (79)	44 (49)	54 (40)	23 (58)
Grade 3/4 AE	209 (34)	57 (37)	151 (33)	184 (33)	25 (41)	26 (34)	9 (23)	140 (33)	42 (53)	9 (30)	6 (43)	26 (29)	36 (27)	10 (25)
Grade 5 AE	37 (6)	13 (9)	24 (5)	32 (6)	5 (8)	6 (8)	1 (3)	25 (6)	4 (5)	1 (3)	2 (14)	5 (6)	9 (7)	2 (5)
Grade 5 related AE	8 (1)	3 (2)	5 (1)	6 (1)	2 (3)	0	0	5 (1)	1 (1)	1 (3)	0	2 (2)	1 (1)	0
Serious AE	198 (32)	59 (39)	138 (30)	171 (31)	27 (44)	25 (33)	10 (25)	129 (30)	39 (49)	9 (30)	9 (64)	23 (26)	39 (29)	6 (15)
AE leading to treatment discontinuation	36 (6)	11 (7)	25 (5)	34 (6)	2 (3)	6 (8)	0	25 (6)	8 (10)	5 (17)	0	3 (3)	6 (4)	2 (5)

Ardizzoni et al, Journal for ImmunoTherapy of Cancer, TAIL final analysis

AE of special interest	224 (36)	63 (41)	160 (35)	212 (38)	12 (20)	28 (37)	7 (18)	170 (40)	35 (44)	12 (40)	5 (36)	22 (24)	36 (27)	12 (30)
Related AE of special interest	187 (30)	55 (36)	131 (28)	177 (32)	10 (16)	25 (33)	7 (18)	140 (33)	28 (35)	9 (30)	4 (29)	19 (21)	28 (21)	10 (25)
Immune-related AE	67 (11)	18 (12)	48 (10)	61 (11)	6 (10)	8 (11)	4 (10)	47 (11)	14 (18)	5 (17)	1 (7)	7 (8)	11 (8)	3 (8)

AE, adverse event; AID, autoimmune disease; CNS, central nervous system; EGFR, epidermal growth factor receptor; ECOG, Eastern Cooperative Oncology Group; Nsqm, non-squamous; PD-1, programmed death 1; PS, performance status; Sqm, squamous.

Ardizzoni et al, Journal for ImmunoTherapy of Cancer, TAIL final analysis

Supplemental Table 2. Efficacy in all patients and selective subgroups

	ORR (95% CI), %	DOR, median (95% CI), months	PFS, median (95%CI), months
All patients (N=615)	11.5 (9.1,14.3)	16.6 (9.7, 20.3)	2.7 (2.3, 2.8)
OAK-like (n=424)	14.4 (11.2,18.1)	14.7 (8.5, 19.6)	2.9 (2.8, 4.1)
Age			
<65 years (n=308)	13.0 (9.4, 17.3)	17.3 (8.4, NE)	2.0 (1.5,2.8)
≥65 years (n=307)	10.1 (7.0, 14.0)	15.2 (7.9, 19.4)	2.9 (2.7, 4.1)
≥75 years (n=76)	13.2 (6.5, 22.9)	18.7 (2.8, 22.8)	4.1 (2.7, 4.7)
Sex			
Male (n=370)	13.0 (9.7,16.8)	17.0 (8.4, 22.8)	2.7 (2.1, 2.9)
Female (n=245)	9.4 (6.0,13.8)	15.2 (8.2, NE)	2.8 (1.7, 3.0)
Histological subtype			
Squamous (n=153)	13.7 (8.7,20.2)	9.5 (5.0, 18.1)	2.9 (2.6, 4.2)
Non-squamous (n=461)	10.8 (8.2,14.0)	18.4 (12.4, 27.5)	2.7 (1.7, 2.8)
ECOG PS at baseline			
0/1 (n=554)	12.5 (9.8,15.5)	17.3 (9.7, 20.3)	2.8 (2.5, 2.9)
2 (n=61)	3.3 (0.4,11.3)	8.9 (5.2, NE)	1.7 (1.4, 2.9)
CNS metastases (n=90)	5.6 (1.8, 12.5)	NE (4.2, NE)	1.4 (1.3, 1.5)
Liver metastases (n=136)	4.4 (1.6, 9.4)	NE (3.9, NE)	1.4 (1.4, 1.5)
Autoimmune disease (n=30)	6.7 (0.8, 22.1)	NE (20.3, NE)	2.9 (1.4, 4.2)
Prior anti-PD-1 therapy (n=40)	5.0 (0.6, 16.9)	11.6 (5.2, NE)	1.6 (1.3, 2.9)
Renal impairment (n=79) ^a	13.9 (7.2, 23.5)	12.7 (4.2, NE)	3.3 (2.7, 5.2)
<i>EGFR</i> positive (n=40) ^b	5.0 (0.6,16.9)	NE (5.5, NE)	1.4 (1.4, 2.0)
<i>ALK</i> positive (n=5)	0	NE (NE, NE)	1.4 (1.3, NE)
PD-L1 BEP			

Ardizzoni et al, Journal for ImmunoTherapy of Cancer, TAIL final analysis

Yes (n=381)	10.5 (7.6, 14.0)	15.5 (7.9, 22.8)	2.6 (1.7,2.8)
No (n=234)	13.2 (9.2, 18.3)	17.3 (8.5, 25.1)	2.8 (2.6,3.1)
PD-L1 expression on TC (BEP)			
Positive (≥1%) (n=213)	12.2 (8.1, 17.4)	16.6 (7.9, 22.8)	2.8 (2.2, 3.3)
Negative (<1%) (n=168)	8.3 (4.6, 13.6)	11.3 (4.0, NE)	1.7 (1.4, 2.8)
PD-L1 expression on TC (BEP)—OAK-like			
Positive (≥1%) (n=147)	15.0 (9.6, 21.8)	16.6 (6.7, 29.1)	3.1 (2.6, 4.6)
Negative (<1%) (n=111)	9.0 (4.4, 15.9)	8.6 (2.8, NE)	2.5 (1.4, 3.1)

BEP, biomarker-evaluable population; CNS, central nervous system; DOR, duration of response; ECOG, Eastern Cooperative Oncology Group; NE, not evaluable; ORR, objective response rate; PD-1, programmed death 1; PD-L1, programmed death-ligand 1; PFS, progression-free survival; PS, performance status; TC, tumor cells.

^aEstimated glomerular filtration rate <60 mL/min/1.73 m². bEGFR positive status includes any EGFR mutation (L858R or Ex.19 deletion, other).